share_log

Is Yunnan Baiyao GroupLtd (SZSE:000538) Using Too Much Debt?

Is Yunnan Baiyao GroupLtd (SZSE:000538) Using Too Much Debt?

雲南白藥集團有限公司(SZSE:000538)是否使用了過多的債務?
Simply Wall St ·  10/03 18:06

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. Importantly, Yunnan Baiyao Group Co.,Ltd (SZSE:000538) does carry debt. But the real question is whether this debt is making the company risky.

霍華德·馬克斯說得很好,與其擔心股價波動,不如擔心永久性損失的可能性...我認識的每個實際投資者都在擔心這個。 當您評估風險時,考慮公司資產負債表是很自然的,因爲債務在企業倒閉時經常涉及。 重要的是,雲南白藥集團股份有限公司(SZSE:000538)確實負債。 但真正的問題是這些債務是否讓公司變得冒險。

Why Does Debt Bring Risk?

爲什麼債務會帶來風險?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. When we examine debt levels, we first consider both cash and debt levels, together.

債務支持企業,直到企業開始付不起債務,無論是通過新資本還是自由現金流。 資本主義的一部分就是「創造性毀滅」過程,失敗的企業會被銀行無情清算。 然而,一種更常見但仍然昂貴的情況是,公司必須以低廉的股價稀釋股東權益,以控制債務。 然而,債務可以取代股權稀釋,是需要資本以高回報率投資增長的公司的極好工具。 當我們審查債務水平時,我們首先考慮現金和債務水平。

What Is Yunnan Baiyao GroupLtd's Net Debt?

雲南白藥集團有限公司的淨債務是多少?

As you can see below, at the end of June 2024, Yunnan Baiyao GroupLtd had CN¥2.15b of debt, up from CN¥1.58b a year ago. Click the image for more detail. However, it does have CN¥16.9b in cash offsetting this, leading to net cash of CN¥14.8b.

如您所見,在2024年6月底,雲南白藥集團有限公司的債務爲215億元,較一年前的158億元有所增加。 點擊圖像查看更多詳細信息。 然而,它擁有169億元的現金,抵消了這一部分,導致淨現金爲148億元。

big
SZSE:000538 Debt to Equity History October 3rd 2024
SZSE:000538債務與股本歷史記錄 2024年10月3日

How Strong Is Yunnan Baiyao GroupLtd's Balance Sheet?

雲南白藥集團有限公司的資產負債表有多堅實?

According to the last reported balance sheet, Yunnan Baiyao GroupLtd had liabilities of CN¥13.8b due within 12 months, and liabilities of CN¥1.18b due beyond 12 months. On the other hand, it had cash of CN¥16.9b and CN¥12.5b worth of receivables due within a year. So it can boast CN¥14.5b more liquid assets than total liabilities.

根據最近報告的資產負債表,雲南白藥集團有限公司有138億人民幣的短期負債,以12個月內到期,和11.8億人民幣的長期負債,12個月後到期。另一方面,它擁有169億人民幣的現金和125億人民幣的應收賬款,一年內到期。因此,它比總負債多擁有145億人民幣的流動資產。

This short term liquidity is a sign that Yunnan Baiyao GroupLtd could probably pay off its debt with ease, as its balance sheet is far from stretched. Succinctly put, Yunnan Baiyao GroupLtd boasts net cash, so it's fair to say it does not have a heavy debt load!

這種短期流動性表明,雲南白藥集團有限公司很可能能夠輕鬆償還其債務,因爲其資產負債表遠未過度拉長。簡而言之,雲南白藥集團有限公司擁有淨現金,因此可以說它沒有沉重的債務負擔!

But the other side of the story is that Yunnan Baiyao GroupLtd saw its EBIT decline by 4.7% over the last year. That sort of decline, if sustained, will obviously make debt harder to handle. The balance sheet is clearly the area to focus on when you are analysing debt. But it is future earnings, more than anything, that will determine Yunnan Baiyao GroupLtd's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

但故事的另一面是,雲南白藥集團有限公司去年EBIt下降了4.7%。如果這種下降持續下去,顯然會使債務更難處理。資產負債表顯然是在分析債務時要集中關注的領域。但更重要的是,未來的收入,遠勝於其他任何因素,將決定雲南白藥集團有限公司未來維持健康資產負債表的能力。因此,如果您側重未來,可以查看這份顯示分析師盈利預測的免費報告。

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. Yunnan Baiyao GroupLtd may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. During the last three years, Yunnan Baiyao GroupLtd generated free cash flow amounting to a very robust 86% of its EBIT, more than we'd expect. That puts it in a very strong position to pay down debt.

但我們的最終考慮也很重要,因爲一家公司無法用紙面利潤支付債務;它需要冷硬現金。雲南白藥集團有限公司的資產負債表上可能有淨現金,但了解企業如何將利潤(EBIT)轉化爲自由現金流程效率很高,因爲這將影響其管理債務的需求和能力。在過去三年中,雲南白藥集團有限公司產生的自由現金流量金額非常強勁,相當於其EBIt的86%,超出我們的預期。這使其處於非常有利的地位來償還債務。

Summing Up

總之

While we empathize with investors who find debt concerning, you should keep in mind that Yunnan Baiyao GroupLtd has net cash of CN¥14.8b, as well as more liquid assets than liabilities. The cherry on top was that in converted 86% of that EBIT to free cash flow, bringing in CN¥4.0b. So is Yunnan Baiyao GroupLtd's debt a risk? It doesn't seem so to us. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. Be aware that Yunnan Baiyao GroupLtd is showing 1 warning sign in our investment analysis , you should know about...

儘管我們對發現債務令人擔憂的投資者表示同情,但您應該記住,雲南白藥集團有着148億人民幣的淨現金,以及比負債更多的流動資產。錦上添花的是,轉化了86%的EBIT爲自由現金流,創造了40億人民幣的現金流入。那麼雲南白藥集團的債務是否存在風險呢?在我們看來似乎並不是。在分析債務水平時,資產負債表是顯然的起點。但並非所有的投資風險都存在於資產負債表中——相反。請注意,雲南白藥集團在我們的投資分析中顯示了1個警示信號,您應該了解...

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

說到底,有時候更容易集中精力關注根本不需要債務的公司。讀者可以免費訪問零淨債務增長股票列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論